From the Department of Pharmacology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Coronary Vasoconstrictor Potential of Triptans: A Review of In Vitro Pharmacologic Data
Article first published online: 7 MAY 2004
Headache: The Journal of Head and Face Pain
Volume 44, Issue Supplement s1, pages S13–S19, May 2004
How to Cite
MaassenVanDenBrink, A. and Saxena, P. R. (2004), Coronary Vasoconstrictor Potential of Triptans: A Review of In Vitro Pharmacologic Data. Headache: The Journal of Head and Face Pain, 44: S13–S19. doi: 10.1111/j.1526-4610.2004.04104.x
- Issue published online: 7 MAY 2004
- Article first published online: 7 MAY 2004
- coronary artery
This article reviews the in vitro pharmacology of the triptans in human isolated coronary arteries. As expected, based on their similar pharmacologic profiles, the triptans cannot be easily differentiated with respect to effects at human isolated coronary arteries. Furthermore, the data show that at therapeutically relevant concentrations, triptans have little potential to cause clinically significant constriction of nondiseased coronary arteries. These data, considered in the context of clinical findings reviewed elsewhere in this supplement, support the conclusion that, while all triptans have the potential to produce small contractions of human isolated coronary arteries, their craniovascular selectivity, when used at therapeutic doses, renders them unlikely to cause serious adverse coronary events in patients with healthy coronary arteries.